ABVC Biopharma Inc
NASDAQ:ABVC
ABVC Biopharma Inc
Cash from Operating Activities
ABVC Biopharma Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ABVC Biopharma Inc
NASDAQ:ABVC
|
Cash from Operating Activities
-$4.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
Cash from Operating Activities
$104.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Karuna Therapeutics Inc
NASDAQ:KRTX
|
Cash from Operating Activities
-$385.8m
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
Moderna Inc
NASDAQ:MRNA
|
Cash from Operating Activities
-$3.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
Cash from Operating Activities
-$533.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-21%
|
See Also
What is ABVC Biopharma Inc's Cash from Operating Activities?
Cash from Operating Activities
-4.2m
USD
Based on the financial report for Dec 31, 2023, ABVC Biopharma Inc's Cash from Operating Activities amounts to -4.2m USD.
What is ABVC Biopharma Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-36%
Over the last year, the Cash from Operating Activities growth was 43%. The average annual Cash from Operating Activities growth rates for ABVC Biopharma Inc have been 2% over the past three years , -36% over the past five years .